Table 3.
Hematologic and nonhematologic toxicities during bortezomib retreatment therapy according to the NCI-CTCAE 4.0.
| Grade | Number of patients in total 30, n (%) | |||
|---|---|---|---|---|
| 1 | 2 | 3 | 4 | |
| Leukopenia | 5 (17) | 9 (30) | 8 (27) | 3 (10) |
| Neutropenia | 3 (10) | 8 (27) | 9 (30) | 5 (17) |
| Anemia | 8 (27) | 15 (50) | 3 (10) | 0 |
| Thrombocytopenia | 5 (17) | 10 (33) | 7 (23) | 6 (20) |
| Creatinine | 2 (7) | 3 (10) | 1 (3) | 0 |
| Anorexia | 8 (27) | 0 | 0 | 0 |
| Nausea | 6 (20) | 1 (3) | 0 | 0 |
| Vomiting | 1 (3) | 1 (3) | 0 | 0 |
| Diarrhea | 2 (7) | 3 (10) | 0 | 0 |
| Constipation | 5 (17) | 3 (10) | 0 | 0 |
| Dyspnea | 3 (10) | 1 (3) | 0 | 0 |
| Pneumonia | 0 | 0 | 5 (17) | 0 |
| Fever/bacteremia | 0 | 0 | 3 (10) | 0 |
| Sensory neuropathy | 10 (33) | 8 (27) | 1 (3) | 0 |
| Motor neuropathy | 4 (13) | 1 (3) | 1 (3) | 0 |
| Pain | 10 (33) | 4 (13) | 0 | 0 |
| Dizziness | 11 (37) | 0 | 0 | 0 |
| Delirium | 1 (3) | 0 | 0 | 0 |
| Insomnia/somnolence | 6 (20) | 0 | 0 | 0 |
| Asthenia | 9 (30) | 11 (37) | 1 (3) | 0 |
| Rash | 2 (7) | 0 | 0 | 0 |
NCI-CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events.